CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC

This article was originally published here

The trial is a multi-center, open-label, and multi-dose Phase Ib/II study that aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor efficacy of the combination in advanced

The post CStone secures approval in China for clinical trial of CS1001, BLU-554 combo for HCC appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply